227 related articles for article (PubMed ID: 10838663)
1. Anti-tumor vaccination in heterozygous congenic F1 mice: presentation of tumor-associated antigen by the two parental class I alleles.
Carmon L; Tzehoval E; Tirosh B; el-Shami KM; Bar-Haim E; Vadai E; Feldman M; Eisenbach L
J Immunother; 2000; 23(3):344-52. PubMed ID: 10838663
[TBL] [Abstract][Full Text] [Related]
2. H-2K double transfectants of tumor cells as antimetastatic cellular vaccines in heterozygous recipients. Implications for the T cell repertoire.
Mandelboim O; Feldman M; Eisenbach L
J Immunol; 1992 Jun; 148(11):3666-73. PubMed ID: 1588053
[TBL] [Abstract][Full Text] [Related]
3. A HER2/NEU-derived peptide, a K(d)-restricted murine tumor rejection antigen, induces HER2-specific HLA-A2402-restricted CD8(+) cytotoxic T lymphocytes.
Ikuta Y; Okugawa T; Furugen R; Nagata Y; Takahashi Y; Wang L; Ikeda H; Watanabe M; Imai S; Shiku H
Int J Cancer; 2000 Aug; 87(4):553-8. PubMed ID: 10918197
[TBL] [Abstract][Full Text] [Related]
4. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens.
Haicheur N; Bismuth E; Bosset S; Adotevi O; Warnier G; Lacabanne V; Regnault A; Desaymard C; Amigorena S; Ricciardi-Castagnoli P; Goud B; Fridman WH; Johannes L; Tartour E
J Immunol; 2000 Sep; 165(6):3301-8. PubMed ID: 10975847
[TBL] [Abstract][Full Text] [Related]
5. Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
Neeley YC; McDonagh KT; Overwijk WW; Restifo NP; Sanda MG
Prostate; 2002 Nov; 53(3):183-91. PubMed ID: 12386918
[TBL] [Abstract][Full Text] [Related]
6. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
7. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity.
Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S
J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity.
Shibagaki N; Udey MC
J Immunol; 2002 Mar; 168(5):2393-401. PubMed ID: 11859130
[TBL] [Abstract][Full Text] [Related]
9. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.
Zitvogel L; Mayordomo JI; Tjandrawan T; DeLeo AB; Clarke MR; Lotze MT; Storkus WJ
J Exp Med; 1996 Jan; 183(1):87-97. PubMed ID: 8551248
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
[TBL] [Abstract][Full Text] [Related]
12. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
14. Immunization with tumor-associated epitopes fused to an endoplasmic reticulum translocation signal sequence affords protection against tumors with down-regulated expression of MHC and peptide transporters.
Sherritt M; Cooper L; Moss DJ; Kienzle N; Altman J; Khanna R
Int Immunol; 2001 Mar; 13(3):265-71. PubMed ID: 11222495
[TBL] [Abstract][Full Text] [Related]
15. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of H-2Kb-low affinity, high affinity, and covalently-bound peptides in anti-tumor vaccination.
Tirosh B; el-Shami K; Vaisman N; Carmon L; Bar-Haim E; Vadai E; Feldman M; Fridkin M; Eisenbach L
Immunol Lett; 1999 Oct; 70(1):21-8. PubMed ID: 10541048
[TBL] [Abstract][Full Text] [Related]
17. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination.
Galea-Lauri J; Darling D; Mufti G; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2002 Aug; 51(6):299-310. PubMed ID: 12111118
[TBL] [Abstract][Full Text] [Related]
18. Enhancing antitumor immune responses: intracellular peptide delivery and identification of MHC class II-restricted tumor antigens.
Wang RF
Immunol Rev; 2002 Oct; 188():65-80. PubMed ID: 12445282
[TBL] [Abstract][Full Text] [Related]
19. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
Tüting T; DeLeo AB; Lotze MT; Storkus WJ
Eur J Immunol; 1997 Oct; 27(10):2702-7. PubMed ID: 9368629
[TBL] [Abstract][Full Text] [Related]
20. Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.
Wälchli S; Kumari S; Fallang LE; Sand KM; Yang W; Landsverk OJ; Bakke O; Olweus J; Gregers TF
Eur J Immunol; 2014 Mar; 44(3):774-84. PubMed ID: 24293164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
